In primary AML, CD34+CD38− LSCs contained lower eIF2α and elevated ATF4 levels as compared to the more differentiated CD34+CD38+ AML cell populations (159), highlighting that there is an increased activity of the ISR in LSCs, and implicating that ATF4 is a potential therapeutic target to eliminate LSCs. This evidence concerns the gene EIF2A and acute myeloid leukemia.